Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070178 | 0.81 | PTGES (0.55) | CYP3A4ALDH1A1PTGESMEN1KMT2A | |
| SCHEMBL4217085 | 0.69 | MAPT (0.55) | CYP3A4ALDH1A1PTGESMEN1KMT2A | |
| SCHEMBL4211589 | 0.69 | MEN1 (0.66) | ALDH1A1PTGESMEN1KMT2AHTT | |
| SCHEMBL4208410 | 0.65 | PTGES (0.64) | ALDH1A1PTGESMEN1KMT2AHTT | |
| SCHEMBL4205329 | 0.64 | PTGES (0.59) | CYP3A4ALDH1A1PTGESMEN1KMT2A | |
| SCHEMBL4205367 | 0.64 | CYP3A4 (0.43) | CYP3A4ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL4215219 | 0.63 | TSHR (0.69) | CYP3A4ALDH1A1PTGESMEN1KMT2A | |
| SCHEMBL4212178 | 0.63 | ALDH1A1 (0.53) | CYP3A4ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL4204068 | 0.62 | ALDH1A1 (0.62) | CYP3A4ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL4200670 | 0.62 | ALDH1A1 (0.58) | ALDH1A1PTGESMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | CYP3A4 323/4885ALDH1A1 253/4885PTGES 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.